Safety Results From Phase I/Ii Study Of The Pi3k Beta Inhibitor Gsk2636771 (G) In Combination With Pembrolizumab (P) In Patients (Pts) With Pd-1 Refractory Metastatic Melanoma (Mm) And Pten Loss.

Hussein Abdul-Hassan Tawbi,Weiyi Peng,Suzanne Phillips,Denai R. Milton,Rodabe Navroze Amaria,Adi Diab,Isabella Claudia Glitza,Sapna Pradyuman Patel,Michael K.K. Wong,Cassian Yee,Jennifer Leigh McQuade,Michael T. Tetzlaff,Alexander J. Lazar,Michael Shephard,Suzanne Cain,Elizabeth M. Burton,Patrick Hwu,Michael A. Davies

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 7|浏览10

暂无评分

摘要

e22000Background: Checkpoint inhibitors (CPI) have improved survival and long-term disease control in 35-40% of pts with MM. Many pts derive no clinical benefit or progress after an initial respons...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要